Last update 01 Nov 2024

TCRDV2 x TCRGV9 x CD276

Basic Info

Related Targets
TCRDV2TCRGV9CD276

Related

1
Drugs associated with TCRDV2 x TCRGV9 x CD276
B7H3-directed GADLEN product
Target
CD276 x TCRDV2 x TCRGV9
Mechanism
CD276 modulators [+2]
Active Org.
Shattuck Labs, Inc.Shattuck Labs, Inc.
Originator Org.
Shattuck Labs, Inc.Shattuck Labs, Inc.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
100 Clinical Results associated with TCRDV2 x TCRGV9 x CD276
Login to view more data
100 Translational Medicine associated with TCRDV2 x TCRGV9 x CD276
Login to view more data
0 Patents (Medical) associated with TCRDV2 x TCRGV9 x CD276
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free